Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 752-753, 2006. First published February 9, 2006; 10.1373/clinchem.2005.064477
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.064477v1
52/4/752    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kupchak, P.
Right arrow Articles by Christenson, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupchak, P.
Right arrow Articles by Christenson, R. H.
Related Collections
Right arrow Informatics and Statistics
Right arrow Laboratory Management
Right arrow General Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:752-753.)
© 2006 American Association for Clinical Chemistry, Inc.

Technical Briefs

Influence of Imprecision on ROC Curve Analysis for Cardiac Markers

Peter Kupchak1, Alan H.B. Wu2,a, Farooq Ghani3, L. Kristen Newby4, E. Magnus Ohman4 and Robert H. Christenson5

(1 Nanogen, Point of Care Diagnostics Division, Toronto, Ontario, Canada;2 Department of Laboratory Medicine, San Francisco General Hospital/University of California, San Francisco, CA;3 Bayer Healthcare Corporation, Tarrytown, NY;4 Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC;5 Department of Pathology, University of Maryland Medical Center, Baltimore, MD;

aaddress correspondence to this author at: Department of Laboratory Medicine, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110; fax 415-206-3045, e-mail wualan{at}labmed2.ucsf.edu)


Abstract

Background: There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events.

Methods: Using existing data from 2 published clinical trials, we used a resampling method to statistically introduce 5%, 10%, and 20% imprecision to results for B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI) and examined its impact on ROC curve analysis.

Results: Superimposition of artificial imprecision produced no significant difference in the area under the ROC curve observed for BNP for diagnosis of heart failure or for cTnI for 30-day risk stratification of patients with ACS.

Conclusion: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease.




The following articles in journals at HighWire Press have cited this article:


Home page
 Ann Clin BiochemHome page
P. O Collinson, G. H Gaynor, and D. C Gaze
Cardiac troponin I measurement using the ACS:180 to predict four-year cardiac event rate
Ann Clin Biochem, March 1, 2008; 45(2): 184 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
S. Choi, D. Park, S. Lee, Y. Hong, S. Kim, and J. Lee
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments
Emerg. Med. J., May 1, 2007; 24(5): 343 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Sakhuja, S. Green, E. M. Oestreicher, P. M. Sluss, E. Lee-Lewandrowski, K. B. Lewandrowski, and J. L. Januzzi Jr.
Amino-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure
Clin. Chem., March 1, 2007; 53(3): 412 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. T. Holmes and K. Buhr
Mathematical Modeling: Assumptions Affect Results.
Clin. Chem., August 1, 2006; 52(8): 1606 - 1608.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. A. Parvin and F. S. Apple
The authors of the article cited above respond:
Clin. Chem., August 1, 2006; 52(8): 1608 - 1609.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al.
Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
Clin. Chem., August 1, 2006; 52(8): 1528 - 1538.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.